Wedbush Decreases Earnings Estimates for Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Research analysts at Wedbush dropped their Q1 2025 EPS estimates for Ascendis Pharma A/S in a research report issued on Wednesday, February 12th. Wedbush analyst Y. Zhong now forecasts that the biotechnology company will post earnings per share of ($1.76) for the quarter, down from their prior forecast of ($1.58). Wedbush currently has a "Outperform" rating and a $181.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($4.36) per share. Wedbush also issued estimates for Ascendis Pharma A/S's Q2 2025 earnings at ($1.24) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($4.84) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at $2.96 EPS and FY2028 earnings at $9.17 EPS.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.64.

ASND has been the subject of several other reports. Oppenheimer cut their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research note on Friday, November 15th. JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Evercore ISI lifted their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research report on Tuesday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 11th. Finally, TD Cowen dropped their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $197.36.

Ascendis Pharma A/S Price Performance

NASDAQ ASND traded down $0.53 on Monday, hitting $154.58. 472,867 shares of the stock were exchanged, compared to its average volume of 516,111. The business's fifty day moving average is $133.61 and its 200 day moving average is $132.72. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The company has a market capitalization of $9.38 billion, a PE ratio of -21.77 and a beta of 0.64.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds have recently made changes to their positions in ASND. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ascendis Pharma A/S during the fourth quarter valued at $28,000. Wilmington Savings Fund Society FSB purchased a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $30,000. Jones Financial Companies Lllp grew its stake in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. increased its stake in shares of Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 328 shares in the last quarter. Finally, Groupama Asset Managment purchased a new stake in Ascendis Pharma A/S in the third quarter worth about $60,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.